One study established a CRISPR screening method using an in situ xenograft model and confirmed that SLC5A3, which is associated with AML cell metabolism, and MARCH5, a key gene for apoptosis, are candidate targets for AML treatment.313. This evidence concerns the gene SLC5A3 and acute myeloid leukemia.